Scilex Holding Company, Inc. (SCLX) - Market Value to Book Value Ratio
Serving as an assessment tool, the Scilex Holding Company (SCLX) price chart helps illustrate the impact of logistical disruptions and sanctions on biopharmaceutical component supplies. Meanwhile, the company's operations rely on the US domestic market, which minimizes external risks, and the current figure stands at -0.04. The business is fighting for leadership in the non-opioid analgesic segment, resisting pressure from regulators and global behemoths.
Scilex Holding (SCLX) - metric breakdowns and financial figures
- share price and consensus valuation forecast:
- market capitalization indicators:
- book capitalization data:
- debt and solvency information:
Debt to Equity Scilex Holding Company|SCLX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Scilex Holding Co.|SCLX - Company Cumulative Debt|Debt to Book Capitalization Ratio Scilex Holding Co.|SCLX - Long-Term Debt Volume|Company Short-Term Debts Scilex Holding Company|Quick Ratio scilexholding.com
- earnings and valuation multiples indicators:
Comprehensive company analysis:Scilex Holding Company
This ratio compares the current market value of shares with the amount of net assets, determining the degree of overvaluation or capital discount relative to book value. Analysis of the market-to-book capitalization ratio allows for an assessment of how the market capitalizes the strategic partnerships of Scilex Holding Company (SCLX) in the non-opioid sector, while sharp fluctuations on the chart may signal hidden financial risks.
Competitors of Scilex Holding Company (SCLX)
BIIB (Biogen Inc.) - Market Cap to Net Assets Ratio|Capitalization to Book Value Ratio NBIX|Market Value to Book Value Ratio Regencell Bioscience Holdings Limited|Capitalization to Book Value Ratio AXSM (Axsome)|Market Capitalization to Book Value Ratio ACAD|XENE - Market-to-Book Ratio|Viking Therapeutics - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio supernus.com SUPN|CPRX - Market Value to Book Value Ratio|Market Value to Book Value DNLI (Denali)|Harmony Pharma (HRMY) - Market Value to Book Value Ratio|Market-to-Book Ratio Biohaven Corp (BHVN)|Market Value to Book Value Ratio Amylyx Pharmaceuticals|trevitherapeutics.com (TRVI) - Market Capitalization to Book Value|Market Capitalization to Book Value Ratio PRAX|Market Cap to Net Assets Ratio Anavex AVXL|Market Capitalization to Book Value Ratio CBLL (CeriBell Corp)|Market Capitalization to Book Value Prothena (PRTA)|ALEC - Market Value to Book Value Ratio|ANNX: Market Value to Book Value Ratio|OMER: Market Capitalization to Book Value Ratio|Market-to-Book Ratio Neurogene Inc (NGNE)|Market Cap to Net Assets Ratio ACIU|Capitalization to Book Value Ratio VYGR (Voyager Corp)|Market Cap to Net Assets Ratio NMRA (Neumora Therapeutics)|TVGN (tevogen.com) - Market Value to Book Value|Market Capitalization to Book Value Ratio ACOG (Alpha Cognition Inc.)|Market Value to Book Value CGTX|IKT - Market Value to Book Value Ratio|Market-to-Book Ratio Cassava Pharma|assertiotx.com (ASRT) - Market Value to Book Value Ratio|COYA (Coya Therapeutics) - Market Value to Book Value Ratio|VTGN (VistaGen Therapeutics, Inc.) - Market Capitalization to Book Value Ratio|Capitalization to Book Value Ratio OVID (Ovid Rx)|Market Capitalization to Book Value Ratio ABOS|Market Capitalization to Book Value CervoMed Corporation|Market Value to Book Value Ratio Alterity Therapeutics Limited ATHE|CLNN: Capitalization to Book Value Ratio|PepGen Corp - Market Capitalization to Book Value Ratio|Market Value to Equity Ratio jupiterneurosciences.com (JUNS)|RLMD (Relmada) - Market Cap to Net Assets Ratio|Annovis Bio Corporation - Market Value to Book Value|GRCE (Grace Therapeutics Inc) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio fireflyneuro.com (AIFF)|Market Value to Book Value Ratio Klotho Neurosciences Inc (KLTO)|NRSN - Market-to-Book Ratio|Market Value to Book Value Ratio Reviva Pharmaceuticals Holdings RVPH|MTVA - Market Cap to Net Assets Ratio|NRXS - Market Value to Book Value Ratio|Market Capitalization to Net Assets HSDT|PASG: Market Capitalization to Book Value Ratio|Neuphoria Therapeutics (NEUP) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Minerva Neurosciences Corp|Capitalization to Book Value Ratio ATHA (Athira Pharma Corp)|Market Cap to Net Assets Ratio ADXN (Addex Therapeutics)|ALZN - Market-to-Book Ratio|Market Value to Book Value Ratio Cyclerion Therapeutics, Inc. CYCN|Market Capitalization to Book Value Protagenic Therapeutics Inc. (PTIX)|Pasithea - Market Capitalization to Book Value Ratio|Cortigent, Inc. (CRGT) - Market Cap to Net Assets Ratio|Avenue Therapeutics (ATXI) - Market Value to Book Value Ratio|BCLI (brainstorm-cell.com) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio CARA|Capitalization to Book Value Ratio CHRO (Chromocell Therapeutics Corp)|Market Value to Book Value Ratio Eliem Therapeutics (ELYM)|intracellulartherapies.com - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio LBPH (Longboard Pharmaceuticals)|marinuspharma.com (MRNS) - Market-to-Book Ratio|NKGN: Market Cap to Net Assets Ratio|NRBO - Market Capitalization to Book Value Ratio|Sage Therapeutics, Inc (SAGE) - Market Value to Book Value Ratio|Synaptogenix, Inc - Market Value to Book Value|Market Value to Book Value Ratio Trevena, Inc.|Market-to-Book Ratio Vigil Neuro VIGL|Market Value to Book Value Ratio Anew Medical, Inc. (WENA)|Market Capitalization to Book Value Cerevel Therapeutics Inc